At Thakur Lab,
We stand at the forefront of drug discovery, leveraging cutting-edge technology and innovative approaches to address unmet medical needs. We specialize in advanced small molecule medicinal chemistry, ligand-based drug design, and structure-guided drug discovery, enhanced by the power of AI. Our focus includes the innovative allosteric modulation of cannabinoid and nicotinic acetylcholine receptors to develop novel therapies for chronic pain, neurodegeneration, substance use disorders, etc.
Latest Research
Negative allosteric modulation of CB1 cannabinoid receptor signaling decreases intravenous morphine self-administration and relapse in mice
Addiction Biology. 2024;29:e13429
Published: August 7, 2024
https://doi.org/10.1111/adb.13429
Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception
Neuropharmacology 257 (2024) 11005
Published: June 25, 2024
https://doi.org/10.1016/j.neuropharm.2024.110052
Explorations of Agonist Selectivity for the α9* nAChR with Novel Substituted Carbamoyl/Amido/Heteroaryl Dialkylpiperazinium Salts and Their Therapeutic Implications in Pain and Inflammation
J. Med. Chem. 2024
Published: May 15, 2024
https://doi.org/10.1021/acs.jmedchem.3c02429
Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation
Cell, Vol. 187, Issue 5, 2024, Pages 1160-1176.e21
Published: February 20, 2024
https://doi.org/10.1016/j.cell.2024.01.032
New Alpha9 nAChR Ligands Based on a 5-(Quinuclidin-3-ylmethyl)-1,2,4-oxadiazole Scaffold
ACS Chem. Neurosci. 2024, 15, 4, 827–843
Published: February 9, 2024
https://doi.org/10.1021/acschemneuro.3c00720
Dose-dependent effects of GAT107, a novel allosteric agonist-positive allosteric modulator (ago-PAM) for the α7 nicotinic cholinergic receptor: a BOLD phMRI and connectivity study on awake rats
Front. Neurosci., Sec. Brain Imaging Methods. Volume 17 – 2023.
Published: June 22, 2023
https://doi.org/10.3389/fnins.2023.1196786